What is NPCE's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for NPCE.

Stock Ratings / Health Care / NPCE / options

CARL (38) SI (44) BWAY (44) CERS (27) ⌘ Pro Terminal →

Neuropace Inc. (NPCE) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is NPCE trading relative to its 50-day, 200-day, and 52-week technical levels?

NPCE last traded at $12.34 (+0.33% on volume of 120,470 shares), positioning the stock -9.40% below its 50-day simple moving average ($13.62) and -17.40% below its 200-day simple moving average ($14.94). Across its 52-week range of $9.22 to $19.60, NPCE sits at the 30.1% percentile with a 14-day RSI of 41.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.1% ($11.22 to $13.46).

$12.34 +0.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.32

Neuropace Inc. (NPCE) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $422.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NPCE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NPCE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Neuropace Inc. (NASDAQ: NPCE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $12.34 (+0.33% 1D, market cap $422.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NPCE ranks #968 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NPCE compare to CARL and SI in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), NPCE carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 77.2%, and ROIC of -23.0%. By comparison, CARL (Carlsmed Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $408.2M) and SI (Shoulder Innovations Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -16.1%, cap $398.3M). Among the 5-stock peer group, NPCE leads on earnings multiple (N/A) while CERS leads on capital efficiency (-15.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NPCE?

▼

Per NPCE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001528287), Neuropace Inc. generated $100.0M in revenue (+25.1% YoY), -$21.5M in net income, and -$11.3M in free cash flow against $105.6M in total assets and $58.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.32 (-0.13%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-16.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NPCE)Realized 20D OHLCV Swing Band: ±9.1%

Deterministic 5-Pillar Attribution (21/100 Composite)

🔍 WHY NPCE SCORES 21/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (29% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 77.2% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$12.68+6.5% Next Q

Q2 (-2Q)

Grade E$13.51-3.6% Next Q

Q3 (-1Q)

Grade E$13.02-5.2% Next Q

Current

Grade E$12.34-11.6% Hist 90D α

Trajectory: E (29) → E (21)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NPCE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NPCE currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.62) and Max Pain ($12.96) forces dealer call-delta covering toward $20.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NPCE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NPCE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 21%NO 79%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.1%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NPCE)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NPCE.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NPCE)

✓Walkthrough of NPCE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NPCE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.98%🛡️ HOLDING TREND SUPPORT

2026-11-03O $13.01H $13.01L $12.30C $12.34VOL 80.9K

RES: $13.15SUP: $11.70SMA50: $13.62SMA200: $14.94

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NPCE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NPCE Butterfly Map → + Track NPCE →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +25.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NPCE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NPCE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NPCE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NPCE)

Health Care Rank #968 of 1016 ⚔️ CARL vs NPCE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NPCE vs. CARL, SI, BWAY, CERS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Neuropace Inc. (NPCE) ranks #968 by composite RQD confidence (21/100, grade E) and #466 by equity capitalization ($422.2M). Within this direct 5-issuer industry benchmark cohort, NPCE leads on earnings valuation at N/A trailing P/E, while CERS leads on capital efficiency and profitability with -15.5% ROIC and — gross margin. SI currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with NPCE at 21/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NPCE ACTIVE Neuropace Inc.	E	21/100	—	77.2%	-23.0%	+0.33%	$422.2M	Benchmark Subject
CARL Carlsmed Inc.	D-	38/100	—	75.3%	-35.0%	+0.47%	$408.2M	/carl-vs-npce →
SI Shoulder Innovations Inc.	D	44/100	—	76.5%	-16.1%	+0.99%	$398.3M	/si-vs-npce →
BWAY BrainsWay Ltd.	D	44/100	—	—	—	-2.38%	$455.9M	/bway-vs-npce →
CERS Cerus Corporation	E	27/100	—	—	-15.5%	+3.51%	$459.5M	/cers-vs-npce →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001528287

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neuropace Inc. (NPCE) reported GAAP revenue of $100.0M (+25.1% vs. FY2024 revenue of $79.9M , and +52.8% cumulative change since FY2023) , GAAP net income of -$21.5M, operating cash flow of -$11.0M, and free cash flow of -$11.3M (+37.9% YoY). On the balance sheet, NPCE closed FY2025 with $105.6M in total assets against $58.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$100.0M	-$21.5M	-$11.0M	-$11.3M	$105.6M	$58.9M
FY2024 (FY)	2024-12-31	$79.9M	-$27.1M	-$17.9M	-$18.3M	$94.6M	$59.5M
FY2023 (FY)	2023-12-31	$65.4M	-$33.0M	-$19.7M	-$19.7M	—	—

3. NPCE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NPCE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NPCE compare to CARL and SI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NPCE?

Where is NPCE trading relative to its 50-day, 200-day, and 52-week technical levels?

NPCE last traded at $12.34 (+0.33% on volume of 120,470 shares), positioning the stock -9.40% below its 50-day simple moving average ($13.62) and -17.40% below its 200-day simple moving average ($14.94). Across its 52-week range of $9.22 to $19.60, NPCE sits at the 30.1% percentile with a 14-day RSI of 41.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.1% ($11.22 to $13.46).

Direct Sub-Reports: NPCE RQD Cockpit NPCE 12M Forecast NPCE Earnings & Move NPCE Dividends & DRIP NPCE Insiders & 13F NPCE Whale Options NPCE Profit Sankey NPCE News & Why

ROARABLE RATING BRIEF • RQD 21/100 (E) ✓ SEC XBRL & RQD VERIFIED

NPCE — Neuropace Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Neuropace Inc. (NPCE) earns a live Roarable RQD composite score of 21/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $12.34 (+0.33% 1D, market capitalization $422.2M).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -23.0%, gross margin of 77.2%, operating margin of -16.3%, and free cash flow yield of -2.54%.
Whale 13F & Options Flow (4/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (3/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of 3.09x.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector and Medical/Dental Instruments industry, with a market capitalization of $0.4B. Per the market data, the company reports a gross margin of 77.2%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Neuropace Inc. (NPCE) reported $100.0M in annual revenue (up from $79.9M in FY2024, +25.1% YoY) and -$21.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($65.4M revenue, -$33.0M net income) through FY2025, NPCE scaled operating cash flow to -$11.0M and free cash flow to -$11.3M, backed by $105.6M in total assets against $58.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 21/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.54% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $9.22 – $19.60 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -16.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should note that the leverage indicated by Debt/Equity of 3.

Key Question #1: Can NPCE sustain or expand its -16.3% operating margin and -23.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $100.0M and free cash flow of -$11.3M, how will capital allocation balance growth reinvestment against $58.9M in total debt?
Key Question #3: How sensitive is NPCE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NPCE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neuropace Inc. (NPCE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NPCE Debate Forum (3) ↓

🟡 MARKET WIRE Stock Titan • 20h ago

A live results call from NeuroPace is set for 1:30 p.m. Pacific on Nov. 12.

Stock Titan report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 23h ago

NeuroPace, Inc. (NPCE) - What Are Brokerages Saying About This Stock?

MarketBeat report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

NeuroPace (NPCE) Slips to $12.56 as Shares Consolidate Below Resistance - Island Reversal

https://www.dars.gov.et/ report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

(NPCE) as a Liquidity Pulse for Institutional Tactics

Stock Traders Daily report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

NeuroPace (NPCE) Projected to Release Earnings on Tuesday

MarketBeat report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

NeuroPace Q3 2026 Earnings Date and Estimates

MarketBeat report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

NPCE Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares - Upward Estimate Revision

https://www.dars.gov.et/ report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 4d ago

NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026

MOUNTAIN VIEW, Calif., October 29, 2026--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NPCE Bull vs. Bear Conversation Board — What's Your Call at $12.34?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NPCE 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $15.38 (+25.0%)

📌 Pinned Debate

Revenue grew from $65.4M in FY 2023 to $100.0M in FY 2025 while the operating loss narrowed from -$27.2M to -$16.3M.

Don't sleep on NPCE's setup in Health Care. Revenue grew from $65.4M in FY 2023 to $100.0M in FY 2025 while the operating loss narrowed from -$27.2M to -$16.3M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (21/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@MidwestValue Agree on the RQD 21/100 quality, though with 1.0 beta I'm scaling in with half-size at $12.30 and keeping dry powder in case we test $11.44.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $9.84 (-20.0%)

Spot @ $12.30

ROIC of -23%, FCF yield of -2.54%, Altman Z of 0.2, and Debt/Equity of 3.09 together signal forensic and cash-generation risk.

I respect the product at Neuropace Inc., but the stock at $12.30 is a different story. ROIC of -23%, FCF yield of -2.54%, Altman Z of 0.2, and Debt/Equity of 3.09 together signal forensic and cash-generation risk.. FCF yield is -2.54% and RQD sits at 21/100 (E) — why pay up here when you can wait for next quarter's numbers?